Merck KGaA, Valo to Use AI for Parkinson’s in $3 Billion Deal

Merck KGaA, a German science group, will use Valo Health Inc.’s AI platform to help discover and develop treatments for Parkinson’s disease and related disorders, in a partnership deal that could be worth more than $3 billion.

The US company will provide a platform that uses advanced AI to uncover disease patterns and find potential targets in a data trove that includes more than 17 million patient records and biobank samples. The deal marks Merck’s second collaboration in neurological conditions this year.

Closely held Valo has struck deals with drugmakers including Novo Nordisk A/S this year even as ...